Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs IRWD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IRWD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

IRWD Overall Winner 6-Pillar Tally: TLPH 1 – 5 IRWD Matrix Metrics: TLPH 4 – 6 IRWD

As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas IRWD carries 35.0/100 (SELL) at $4.86 (12.3x Forward P/E, 62.9% operating margin).

  • Composite vs. Pillar Nuance: While TLPH currently prints a higher short-term Unified Composite Score (37.1/100 SELL vs. IRWD 35.0/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -1474700.0% operating margin) and revenue trajectory (+9.0% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although IRWD compares more favorably head-to-head, both TLPH (37.1/100 SELL) and IRWD (35.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 76.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs IRWD
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
IRWD NASDAQ Head-to-Head Winner
Ironwood Pharmaceuticals, Inc. - Class A
Pharmaceutical Preparations
$4.86
+0.62% 1D
Market Cap $802.9M
TTM Revenue $400M
Forward P/E 12.3x
Beta / 30D Vol 1.37β · 54% Vol
Unified Composite Score
35.0 / 100 SELL
Tech 50.0 Fund 34.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 76
RSI-14: 76.0 · SMA20: $4.00 · SMA50: $3.98

6-Pillar Scorecard Institutional Category Breakdown (TLPH 1 – 5 IRWD)

Columns: Metric · TLPH · IRWD
1. Valuation Multiples TLPH
Forward P/E 1.0x 12.3x
Trailing P/E 1.0x 5.4x
PEG Ratio N/M N/M
EV / Revenue N/M 2.6x
2. Growth & Scale IRWD
Revenue Growth (YoY) +0.0% +9.0%
Earnings Growth (YoY) +0.0% +57.0%
TTM Revenue (USD) $1,000 $400M
Market Cap $53.7M $802.9M
3. Profitability & Quality IRWD
Gross Margin N/A 76.4%
Operating Margin -1474700.0% 62.9%
Net Profit Margin 0.0% 37.4%
Return on Equity (ROE) -143.4% -574.7%
4. Balance Sheet & Cash Flow IRWD
Cash Generation (TTM) -$15M EBITDA $205M
Cash Flow Margin N/A 51.3%
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE $250M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IRWD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 118.4% (100th %ile) 63.1% (6th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat IRWD
OpEx & R&D Intensity N/A 13.5% of Rev ($54M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (4) vs IRWD (6)
Institutional Metric TLPH IRWD Criterion Row Edge
Market Capitalization
Scale
$53.7M $802.9M Larger Scale IRWD
Trailing P/E Ratio
Valuation
1.0x 5.4x Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x 12.3x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% +9.0% Higher Growth IRWD
Operating Margin (TTM)
Profitability
-1474700.0% 62.9% Higher Margin IRWD
Net Profit Margin
Profitability
0.0% 37.4% Higher Margin IRWD
Return on Equity (ROE)
Capital Efficiency
-143.4% -574.7% Higher ROE TLPH
52-Week Range Position
Momentum
20% ($1–$2) 68% ($3–$6) Stronger Trend IRWD
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol 1.37β · 54% Vol Lower Realized Risk IRWD
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 35.0 / 100 (SELL) Higher Composite TLPH
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $400M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 76.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) $205M ($250M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IRWD +59.15 pp
TLPH: -20.29% · IRWD: +38.86%
3M Horizon IRWD +41.61 pp
TLPH: -28.85% · IRWD: +12.76%
6M Horizon IRWD +30.88 pp
TLPH: +7.98% · IRWD: +38.86%
1Y Horizon IRWD +62.22 pp
TLPH: -18.01% · IRWD: +44.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs IRWD. Trailing 12-month operating profitability (TLPH -1474700.0% vs IRWD 62.9%) and valuation multiples (TLPH 1.0x vs IRWD 12.3x Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
IRWD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$400M
Gross Margin76.4%
Op. Margin62.9%
ROE / Fwd P/E-574.7% · 12.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IRWD CONSOLIDATION
134d in phase · OBV ACCUMULATION
Current IV 63.1%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IRWD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IRWD Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $802.9M market capitalization and 62.9% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($54M)
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs IRWD Key Questions & Quantitative Answers

As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas IRWD carries 35.0/100 (SELL) at $4.86 (12.3x Forward P/E, 62.9% operating margin). Composite vs. Pillar Nuance: While TLPH currently prints a higher short-term Unified Composite Score (37.1/100 SELL vs. IRWD 35.0/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -1474700.0% operating margin) and revenue trajectory (+9.0% vs. +0.0% YoY). Defensive Composite Rating Caution: Although IRWD compares more favorably head-to-head, both TLPH (37.1/100 SELL) and IRWD (35.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 76.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IRWD leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with IRWD at +9.0% YoY revenue growth and +57.0% YoY earnings growth on $400M TTM revenue (76.4% gross margin, 62.9% operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus $400M for IRWD. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($54M) (0 disclosures) for IRWD.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas IRWD trades at 12.3x Forward P/E, 5.4x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (51.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus IRWD (-574.7% ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, IRWD carries 63.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.37β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.